Powering 1 in 5 NHS skin cancer pathways

NEWS

Introducing DERM Zero

DERM Zero is a world-first: Class III regulated AI delivering autonomous skin cancer assessment from a standard smartphone.

Built on six years of NHS deployment, DERM Zero enables healthcare providers in primary care, pharmacy or community settings, to perform clinical grade skin cancer checks in seconds. No hospital appointment. No specialist equipment.

Find us at HLTH

Skin Analytics and our partners will be sharing more about the role of autonomous AI in improving patient access to skin cancer diagnosis.

Find us at the following sessions:

See DERM in action

Find us in the AI Zone at Stand E82 ​

KEYNOTE
Skin in the game: What’s next for AI-powered dermatology?

Tuesday 16 June | 1:55pm

Skin Analytics CEO Neil Daly reveals our latest breakthrough and its impact on how patients access dermatology

PANEL
Pick your fighter: Europe’s play in the AI race

Wednesday 17 June | 3:30pm

Skin Analytics CEO Neil Daly joins Tandem Health’s Lukas Saari and Nabla’s Laurie Soffiati to discuss how leading AI companies are leveraging the EU’s regulatory foothold to compete, scale, and endure?

PROVIDER SPOTLIGHT
Chelsea and Westminster Hospital NHS Foundation Trust

Wednesday 17 June | 12:20pm

Marcela Vizcaychipi, CCIO at Chelsea and Westminster NHS Foundation Trust presents a case study on deploying Skin Analytics’ DERM, a highly regulated AI as a Medical Device for cancer detection in to urgent skin cancer pathways, and its impact on capacity, access and clinical safety

AI ZONE
Transforming skin cancer detection with AI: The AI healthcare race Europe can win

Wednesday 17 June | 11:10am

Skin Analytics CEO Neil Daly will share examples of how providers are using AI to autonomously discharge patients without review by a clinician in primary, acute, and at-home pathways.

FRINGE EVENT
UK Department for Business and Trade: Accelerating AI development in the UK

Monday 15 June | 2:30pm

Skin Analytics Head of NHS Commercial Darren Jalink shares a case study on the deployment of DERM in a high volume NHS skin cancer pathway.

Book a meeting

Speak to our team to find out how smartphone-based skin cancer assessment can transform your skin cancer pathway